Glaukos (GKOS) to Release Quarterly Earnings on Monday

Glaukos (NYSE:GKOS) is scheduled to be issuing its quarterly earnings data after the market closes on Monday, November 4th. Analysts expect the company to announce earnings of ($0.52) per share for the quarter. Parties interested in listening to the company’s conference call can do so using this link.

Glaukos (NYSE:GKOS) last posted its quarterly earnings results on Wednesday, July 31st. The medical instruments supplier reported ($0.52) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.52). The firm had revenue of $95.70 million for the quarter, compared to the consensus estimate of $88.86 million. Glaukos had a negative net margin of 47.39% and a negative return on equity of 22.51%. The business’s revenue was up 19.0% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.55) earnings per share. On average, analysts expect Glaukos to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Glaukos Price Performance

NYSE:GKOS opened at $131.70 on Friday. The company has a debt-to-equity ratio of 0.19, a quick ratio of 4.67 and a current ratio of 5.48. The company has a 50-day moving average of $129.70 and a 200-day moving average of $119.17. Glaukos has a 52 week low of $59.22 and a 52 week high of $139.51. The company has a market capitalization of $7.24 billion, a price-to-earnings ratio of -40.40 and a beta of 1.02.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on GKOS. Truist Financial upped their price objective on Glaukos from $145.00 to $152.00 and gave the company a “buy” rating in a research note on Monday, October 14th. BTIG Research increased their price objective on Glaukos from $131.00 to $139.00 and gave the stock a “buy” rating in a research note on Wednesday, August 28th. Morgan Stanley lifted their price objective on Glaukos from $100.00 to $120.00 and gave the company an “equal weight” rating in a report on Monday, July 15th. Wells Fargo & Company upped their target price on shares of Glaukos from $120.00 to $135.00 and gave the stock an “overweight” rating in a report on Thursday, August 1st. Finally, Stifel Nicolaus lifted their price target on shares of Glaukos from $130.00 to $145.00 and gave the company a “buy” rating in a report on Tuesday, September 3rd. Four equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to MarketBeat.com, Glaukos currently has a consensus rating of “Moderate Buy” and a consensus target price of $130.45.

Insider Activity at Glaukos

In other news, Director Aimee S. Weisner sold 25,000 shares of the business’s stock in a transaction on Thursday, August 8th. The stock was sold at an average price of $120.00, for a total transaction of $3,000,000.00. Following the completion of the sale, the director now owns 30,119 shares in the company, valued at $3,614,280. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In other news, Director Aimee S. Weisner sold 25,000 shares of Glaukos stock in a transaction that occurred on Thursday, August 8th. The shares were sold at an average price of $120.00, for a total transaction of $3,000,000.00. Following the completion of the sale, the director now owns 30,119 shares in the company, valued at $3,614,280. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Marc Stapley sold 6,250 shares of the business’s stock in a transaction that occurred on Thursday, August 15th. The stock was sold at an average price of $125.93, for a total transaction of $787,062.50. Following the sale, the director now directly owns 34,076 shares of the company’s stock, valued at approximately $4,291,190.68. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 41,525 shares of company stock valued at $5,142,029 over the last quarter. Corporate insiders own 6.40% of the company’s stock.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.